M Notes on the design of bioequivelence study: emtricitabine/tenofovir/efavirenz PDF Guideline/guidance
M Notes on the design of bioequivelence study: ethambutol/isoniazid (16 January 2018) PDF Guideline/guidance
M Notes on the design of bioequivelence study: ethambutol/isoniazid/pyrazinamide/rifampicin PDF Guideline/guidance
M Notes on the design of bioequivelence study: ethambutol/isoniazid/rifampicin PDF Guideline/guidance
M Notes on the design of bioequivelence study: isoniazid/pyrazinamide/rifampicin PDF Guideline/guidance
IS Notice of Suspension/Delisting – Centre Humanitaire des Métiers de la Pharmacie (CHMP) PDF Information note
M Notification of a change(s) to the key information of a product approved by a stringent regulatory authority (SRA) (4 December 2015) DOCX Application form
M Notification of an outcome of the national registration provided by the participating company to WHO-PQT, Annex 7 DOCX Template
M Notification of outcomes of national registration procedure by the NRA, Appendix 3, Part C PDF Template
VCP Number of batches required for testing of physical/chemical properties (VCP Advice to manufacturers series) PDF Guideline/guidance
M One-third of antimalarial medicines tested in six African countries fail to meet international quality standards (issued 25 February 2011) PDF Information note